Evidence map›Paper›PMID 39935991›Full record

ArticleSaudi journal of medicine & medical sciences

Outcomes of Patients with Hematological Malignancies Admitted to the Intensive Care Unit at a Tertiary Care Center in Saudi Arabia.

Ghazi Saud Alotaibi, Yazeed Alekrish, Fares Aldokhayel, Abdullah Alassaf, Musa Alzahrani, Mansour Aljabry, Bader Alshehri, Fatimah Alshalati, Sarah Sewaralthahab, Farjah Algahtani and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi journal of medicine & medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ghazi Saud AlotaibiDivision of Hematology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Yazeed AlekrishDepartment of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Fares AldokhayelDepartment of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Abdullah AlassafDepartment of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Musa AlzahraniDivision of Hematology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Mansour AljabryDepartment of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Bader AlshehriDepartment of Critical Care, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Fatimah AlshalatiDivision of Hematology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Sarah SewaralthahabDivision of Hematology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Farjah AlgahtaniDivision of Hematology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Khalid AlsalehDivision of Hematology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Ahmad JamalDivision of Hematology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Aamer AleemDivision of Hematology, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with hematological malignancies (HM) are at risk for complications, including neutropenia and admission to the intensive care unit (ICU). Granulocyte colony-stimulating factors (GCSF) can accelerate progenitor cells' proliferation and differentiation, and thus compensate for neutropenia. In patients with HM admitted to ICUs in Saudi Arabia, the outcome and impact of GCSF use on neutropenia duration and severity is understudied. Objective: To evaluate the outcome and impact of GCSF on neutropenia in patients with HM admitted to the ICU of a tertiary care center in Saudi Arabia. Methods: This retrospective study included all consecutive patients diagnosed with an HM admitted to the ICU at King Saud University Medical City, Riyadh, Saudi Arabia, from 2018 to 2022. Data on demographics, clinical information, ICU admission, and outcomes were collected. Results: A total of 44 patients with HM admitted to the ICU were included, of which 43.2% were females and the mean age was 50.2 ± 21.1 years. The mean length of ICU stay was 12.3 ± 14.7 (range: 0-62) days. ICU mortality was 61.4%, with no further mortality within 90 days after discharge. There was no significant association between survival and age ( Conclusion: Patients with hematological malignancies who were admitted to an ICU in Saudi Arabia had a high mortality, regardless of neutropenia or the use of granulocyte colony-stimulating factor.

Indexed as

Granulocyte colony-stimulating factorhematological malignanciesintensive care unitmortalityneutropeniaSaudi Arabiasurvival

Identifiers

PMID39935991
PMCPMC11809755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.